⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9861235 | 0.80 | NQO1 (0.31) | — | |
| SCHEMBL5555218 | 0.79 | — | — | |
| SCHEMBL27927880 | 0.77 | MGAM (0.35) | — | |
| SCHEMBL20917228 | 0.77 | ALDH1A1 (0.38) | — | |
| SCHEMBL27548897 | 0.75 | — | — | |
| SCHEMBL1839645 | 0.74 | — | — | |
| SCHEMBL5146752 | 0.74 | — | — | |
| SCHEMBL11756433 | 0.74 | EPHX1 (0.45) | — | |
| SCHEMBL25418892 | 0.72 | — | — | |
| SCHEMBL27988348 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1996008468-A1 | CARBAMOYLOXY AMINE COMPOUNDS | H. LUNDBECK A/S (DK) | 1996-03-21 | — | — | WO | claimed |
| WO-2024043651-A1 | PEPTIDE FOR IMPROVING SOLUBILITY, AND COMPOSITION FOR IMPROVING SOLUBILITY COMPRISING SAME | ㈜에빅스젠 | 2024-02-29 | — | — | WO | disclosed |
| CN-102821602-A | Fatty acid fumarate derivatives and their uses | CATABASIS PHARMACEUTICALS INC | 2012-12-12 | — | — | CN | disclosed |
| EP-1841460-A2 | THERAPEUTIC FORMULATIONS FOR THE TREATMENT OF BETA-AMYLOID RELATED DISEASES | Neurochem (International) Limited (CH) | 2007-10-10 | — | — | EP | disclosed |
| WO-2007049098-A2 | THERAPEUTIC FORMULATIONS FOR THE TREATMENT OF BETA-AMYLOID RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-05-03 | — | — | WO | disclosed |
| US-7030136-B2 | Use of phanquinone for the treatment or prevention of memory impairment | PRANA BIOTECHNOLOGY LIMITED (AU) | 2006-04-18 | — | — | US | disclosed |
| EP-1585520-A1 | THERAPEUTIC FORMULATIONS FOR THE TREATMENT OF BETA-AMYLOID RELATED DISEASES | Neurochem (International) Limited (CH) | 2005-10-19 | — | — | EP | disclosed |
| US-20050031651-A1 | Administering a combination of an agent that treats an amyloid-P disease, neurodegeneration, or cellular toxicity; and said second agent is a therapeutic drug or nutritive supplement | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2005-02-10 | — | — | US | disclosed |
| EP-1140090-B1 | USE OF PHANQUINONE FOR THE TREATMENT OR PREVENTION OF MEMORY IMPAIRMENT | GEROLYMATOS P N SA (GR) | 2004-12-22 | — | — | EP | disclosed |
| WO-2004058258-A1 | THERAPEUTIC FORMULATIONS FOR THE TREATMENT OF BETA-AMYLOID RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2004-07-15 | — | — | WO | disclosed |
| US-20030055078-A1 | Use of phanquinone for the treatment or prevention of memory impairment | P. N. GEROLYMATOS S.A. | 2003-03-20 | — | — | US | disclosed |
| EP-1140090-A1 | USE OF PHANQUINONE FOR THE TREATMENT OR PREVENTION OF MEMORY IMPAIRMENT | P.N. GEROLYMATOS S.A. (GR) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000040244-A1 | USE OF PHANQUINONE FOR THE TREATMENT OR PREVENTION OF MEMORY IMPAIRMENT | P.N. GEROLYMATOS S.A. (GR) | 2000-07-13 | — | — | WO | disclosed |
| WO-1996008468-A1 | CARBAMOYLOXY AMINE COMPOUNDS | H. LUNDBECK A/S (DK) | 1996-03-21 | — | — | WO | disclosed |